A61P 13/06
Anti-spasmodics
A61P13/06 (Anti-spasmodics) appears on 209 US grants and 306 published applications in this corpus.
Search patents in A61P- Granted patents
- 209
- Published applications
- 306
- Assignees
- 147
- Inventors
- 635
- Latest grant
- 6 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 3 | 1 |
| 2002 | 5 | 4 |
| 2003 | 4 | 6 |
| 2004 | 3 | 13 |
| 2005 | 4 | 13 |
| 2006 | 6 | 24 |
| 2007 | 12 | 20 |
| 2008 | 7 | 28 |
| 2009 | 13 | 16 |
| 2010 | 26 | 35 |
| 2011 | 16 | 26 |
| 2012 | 10 | 9 |
| 2013 | 15 | 15 |
| 2014 | 20 | 15 |
| 2015 | 10 | 8 |
| 2016 | 10 | 8 |
| 2017 | 4 | 7 |
| 2018 | 9 | 6 |
| 2019 | 3 | 12 |
| 2020 | 5 | 9 |
| 2021 | 1 | 5 |
| 2022 | 5 | 4 |
| 2023 | 1 | 6 |
| 2024 | 2 | 9 |
| 2025 | 1 | 5 |
| 2026 | 2 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Viral vectors for treating neurogenic detrusor overactivity6 Jan 2026US 12,516,326 B2Assistance Publique-Hopitaux de Paris
- Viral vectors for treating neurogenic detrusor overactivity6 Jan 2026US 12,516,330 B2Assistance Publique-Hopitaux de Paris
- Biphenyl compounds useful as muscarinic receptor antagonists25 Mar 2025US 12,258,316 B2Theravance Biopharma R&D IP, LLC
- Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders10 Dec 2024US 12,161,703 B2Revance Therapeutics, Inc.
- Beta-adrenergic agonist and muscarinic antagonist compositions and methods of using30 Jul 2024US 12,048,712 B2Bonafide Health, LLC
- Viral Vectors For Treating Neurogenic Detrusor Overactivity3 Sep 2026US 2026/0258426 A1Assistance Publique-Hopitaux de Paris
- Ammonia oxidizing microorganisms for use and delivery to the intranasal system12 Mar 2026US 2026/0069642 A1Aobiome LLC
- Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders30 Oct 2025US 2025/0332232 A1Revance Therapeutics, Inc.
- Ammonia oxidizing microorganisms for use and delivery to the intranasal system24 Jul 2025US 2025/0235489 A1
- Viral Vectors For Treating Neurogenic Detrusor Overactivity19 Jun 2025US 2025/0197867 A1Assistance Publique-Hopitaux de Paris
Most cited
By later US patents
- Antisense oligonucleotides against VR1125US 7,662,948 B2Gruenenthal GmbH · 2010
- Highly compressible ethylcellulose for tableting103US 6,592,901 B2Hercules Incorporated · 2003
- Dibenzo chromene derivatives and their use as ERβ selective ligands93US 7,157,492 B2Wyeth · 2007
- Dibenzo chromene derivatives and their use as ERβ selective ligands89US 7,671,084 B2Wyeth · 2010
- Basic derivatives of glutamic acid and aspartic acid as gastrin or cholecystokinin antagonists60US 5,587,479 ARotta Research Laboratorium S.p.A. · 1996